These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 34942512

  • 1. PD-L1 expression is regulated by microphthalmia-associated transcription factor (MITF) in nodular melanoma.
    Vučinić D, Grahovac M, Grahovac B, Vitezić BM, Kovač L, Belušić-Gobić M, Zamolo G.
    Pathol Res Pract; 2022 Jan; 229():153725. PubMed ID: 34942512
    [Abstract] [Full Text] [Related]

  • 2. The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells.
    Genovese G, Ghosh P, Li H, Rettino A, Sioletic S, Cittadini A, Sgambato A.
    Cell Cycle; 2012 Jun 01; 11(11):2206-15. PubMed ID: 22647378
    [Abstract] [Full Text] [Related]

  • 3. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R.
    PLoS One; 2008 Jul 16; 3(7):e2734. PubMed ID: 18628967
    [Abstract] [Full Text] [Related]

  • 4. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.
    Hum Pathol; 2013 Sep 16; 44(9):1902-11. PubMed ID: 23664541
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A, Quirit JG, Khouri MG, Firestone GL.
    Mol Carcinog; 2017 Jan 16; 56(1):49-61. PubMed ID: 26878440
    [Abstract] [Full Text] [Related]

  • 6. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
    Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F.
    Mol Cancer Res; 2021 Jul 16; 19(7):1221-1233. PubMed ID: 33741716
    [Abstract] [Full Text] [Related]

  • 7. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation.
    Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI.
    Biochem Biophys Res Commun; 2007 Mar 16; 354(3):830-5. PubMed ID: 17266927
    [Abstract] [Full Text] [Related]

  • 8. miR-211 and MITF modulation by Bcl-2 protein in melanoma cells.
    De Luca T, Pelosi A, Trisciuoglio D, D'Aguanno S, Desideri M, Farini V, Di Martile M, Bellei B, Tupone MG, Candiloro A, Regazzo G, Rizzo MG, Del Bufalo D.
    Mol Carcinog; 2016 Dec 16; 55(12):2304-2312. PubMed ID: 26599548
    [Abstract] [Full Text] [Related]

  • 9. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
    Wrede N, Hoffmann I, Vollbrecht C, Koch I, Wolkenstein P, Klauschen F, Capper D, von Laffert M, Jurmeister P.
    Pathol Res Pract; 2022 Jan 16; 229():153689. PubMed ID: 34844086
    [Abstract] [Full Text] [Related]

  • 10. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2.
    Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, Wang C, Hu DN, Qu J, Tu L.
    PLoS One; 2012 Jan 16; 7(7):e40967. PubMed ID: 22848417
    [Abstract] [Full Text] [Related]

  • 11. Pro-survival role of MITF in melanoma.
    Hartman ML, Czyz M.
    J Invest Dermatol; 2015 Feb 16; 135(2):352-358. PubMed ID: 25142731
    [Abstract] [Full Text] [Related]

  • 12. Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
    Park S, Cho S, Kim M, Park JU, Jeong EC, Choi E, Park JH, Lee C, Chang MS.
    J Am Acad Dermatol; 2018 Nov 16; 79(5):843-852. PubMed ID: 29792909
    [Abstract] [Full Text] [Related]

  • 13. Frequent mutations in the MITF pathway in melanoma.
    Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, Vemula S, Burrell AS, Agrawal NS, Lin JC, Banister CE, Buckhaults P, Rosenberg SA, Bastian BC, Pavan WJ, Samuels Y.
    Pigment Cell Melanoma Res; 2009 Aug 16; 22(4):435-44. PubMed ID: 19422606
    [Abstract] [Full Text] [Related]

  • 14. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.
    Nature; 2005 Jul 07; 436(7047):117-22. PubMed ID: 16001072
    [Abstract] [Full Text] [Related]

  • 15. Activation of the long terminal repeat of human endogenous retrovirus K by melanoma-specific transcription factor MITF-M.
    Katoh I, Mírová A, Kurata S, Murakami Y, Horikawa K, Nakakuki N, Sakai T, Hashimoto K, Maruyama A, Yonaga T, Fukunishi N, Moriishi K, Hirai H.
    Neoplasia; 2011 Nov 07; 13(11):1081-92. PubMed ID: 22131883
    [Abstract] [Full Text] [Related]

  • 16. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cells.
    Hartman ML, Czyz M.
    Arch Dermatol Res; 2020 Jul 07; 312(5):385-392. PubMed ID: 31624899
    [Abstract] [Full Text] [Related]

  • 17. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
    Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, Bröcker EB, Becker JC.
    Clin Cancer Res; 2007 Nov 01; 13(21):6344-50. PubMed ID: 17975146
    [Abstract] [Full Text] [Related]

  • 18. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.
    Wellbrock C, Arozarena I.
    Pigment Cell Melanoma Res; 2015 Jul 01; 28(4):390-406. PubMed ID: 25818589
    [Abstract] [Full Text] [Related]

  • 19. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S, Leone DA, Biswas A, Deng A, Jukic D, Singh R, Sundram U, Mahalingam M.
    Hum Pathol; 2018 Dec 01; 82():206-214. PubMed ID: 30120967
    [Abstract] [Full Text] [Related]

  • 20. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A, Orgaz JL, Baquero P, Ali Z, Moreno A, Tiana M, Gómez V, Riveiro-Falkenbach E, Cañadas C, Zazo S, Bertolotto C, Davidson I, Rodríguez-Peralto JL, Palmero I, Rojo F, Jensen LD, del Peso L, Jiménez B.
    Neoplasia; 2014 Jun 01; 16(6):529-42. PubMed ID: 25030625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.